Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

Dr Marco Bergonti (Istituto Cardiocentro Ticino, CH) to discuss the key takeaways from the ANTWOORD II Trial.

In this study, 605 heart failure patients undergoing atrial fibrillation ablation were enrolled to receive an ANTWERP Score, which aimed to predict LVEF recovery. 70% of patients were categorised as 'responders', patients identified as those who could benefit the most from AF ablation.

Results suggest that responders to the study achieved 10 times less deaths and heart transplantations, 10 times less heart failure hospitalisations and 8 times more positive left ventricular remodeling.

Questions:
-Can you provide a brief overview of the ANTWOORD I trial and explain the research question that -ANTWOORD II aims to address?
-Could you elaborate on the ANTWERP scoring system and how it is used in the study?
-Can you describe the study design, entry criteria, and patient population in detail?
-What were the main findings of the study and what conclusions can be drawn from them?
-What are the clinical implications of the study?
-What are some limitations of the study that should be considered?
-What are the next steps?

Recorded from EHRA 2023, Barcelona.

Visit Radcliffe Cardiology:

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook:
Follow us on Twitter:

Чтобы скачать видео "EHRA 23: ANTWOORD II: LVEF Recovery After Atrial Fibrillation Ablation in Heart Failure Patients" передвинте ползунок вправо